Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $7.2 million.

  • Dna X's Cash from Financing Activities rose 5107857.14% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year increase of 40186.4%. This contributed to the annual value of $4.6 million for FY2024, which is 160808.82% up from last year.
  • Per Dna X's latest filing, its Cash from Financing Activities stood at $7.2 million for Q3 2025, which was up 5107857.14% from $4.8 million recorded in Q2 2025.
  • Dna X's 5-year Cash from Financing Activities high stood at $18.6 million for Q4 2021, and its period low was -$37000.0 during Q1 2023.
  • Its 5-year average for Cash from Financing Activities is $3.4 million, with a median of $382000.0 in 2023.
  • As far as peak fluctuations go, Dna X's Cash from Financing Activities soared by 67620000.0% in 2022, and later crashed by 51111.11% in 2023.
  • Dna X's Cash from Financing Activities (Quarter) stood at $18.6 million in 2021, then crashed by 100.19% to -$36000.0 in 2022, then dropped by 2.78% to -$37000.0 in 2023, then soared by 2262.16% to $800000.0 in 2024, then soared by 795.62% to $7.2 million in 2025.
  • Its Cash from Financing Activities stands at $7.2 million for Q3 2025, versus $4.8 million for Q2 2025 and $6.4 million for Q1 2025.